Metabolic · Investigational
Cotadutide
No lawful US pathway
01 · Overview
Cotadutide (MEDI0382) is a dual agonist of the GLP-1 and glucagon receptors formulated as a peptide for once-daily subcutaneous injection (PMID 29945727). It was designed to combine GLP-1-mediated improvements in glucose control and satiety with glucagon receptor activation aimed at increasing energy expenditure and reducing liver fat.
It was studied in obesity with type 2 diabetes, diabetic kidney disease, and metabolic dysfunction-associated steatohepatitis (MASH).
02 · Research summary & key findings
In a phase 2a study in overweight or obese adults with type 2 diabetes, cotadutide reduced post-meal glucose and body weight versus placebo over 41 days (PMID 29945727). In the 19-week PROXYMO trial in biopsy-proven MASH with fibrosis, the higher dose reduced liver fat fraction and liver enzymes, with mostly gastrointestinal adverse events (PMID 38729399). In a phase 2b trial in type 2 diabetes with chronic kidney disease, it reduced urinary albumin-to-creatinine ratio by up to about 50 percent versus placebo (PMID 39218393).
03 · Regulatory status
Cotadutide is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
No lawful pathway today
Cotadutide is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 13 FDA-approved compounds in Metabolic
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for metabolic health and weight?
Cotadutide is an investigational compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on metabolic health and weight, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection
References
- [1]MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study Lancet, 2018. PMID 29945727
- [2]Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis Clin Gastroenterol Hepatol, 2024. PMID 38729399
- [3]A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease Kidney Int, 2024. PMID 39218393
Primary literature
- PubMed: "Cotadutide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Cotadutide"
Registered interventional and observational studies, including status and phase.
- PubChem: "Cotadutide"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Metabolic
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.